Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6543
    +0.0020 (+0.31%)
     

  • OIL

    84.39
    +0.82 (+0.98%)
     

  • GOLD

    2,355.30
    +12.80 (+0.55%)
     

  • Bitcoin AUD

    98,030.97
    +1,418.38 (+1.47%)
     

  • CMC Crypto 200

    1,387.64
    -8.89 (-0.64%)
     

  • AUD/EUR

    0.6103
    +0.0030 (+0.49%)
     

  • AUD/NZD

    1.0987
    +0.0030 (+0.27%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,117.56
    +38.70 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,056.38
    +139.10 (+0.78%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Why New COVID Strains May Mean More Revenue for Pfizer and Moderna

Adria Cimino, The Motley Fool
·4-min read

In this Motley Fool Live video, recorded on Feb. 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss how Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and others are faring, how they plan to deal with new variants, and what all of this means for revenue. Corinne Cardina: There has been a lot of different research about which vaccines, how they're holding up against different variants.

Continue reading